BioGX
1500 First Ave North, C123
Birmingham
Alabama
35203
Tel: 205-250-8055
Fax: 205-449-8055
Website: http://biogx.com/
Email: info@biogx.com
About BioGX
BioGX develops molecular products and provides partner-specified formulation and manufacturing services for molecular tests on a platform of a partner’s choice. The company applies its proprietary platform-agnostic reagent technology to offer products and contract services across a variety of real-time PCR and Next Generation Sequencing platforms. The Sample-ReadyTM technology is at the core of all product offerings for Clinical, Food Safety, Pharma and Water Quality testing. BioGX products are available worldwide through direct sales and distributors.YEAR FOUNDED:
2007
LEADERSHIP:
CEO: Shazi Iqbal
JOBS:
Please click here for BioGX job opportunities.
PRODUCTS:
All Products
16 articles about BioGX
-
BioGX Expands PCR Test Menu at State Departments of Health
1/11/2024
BioGX, a leading global provider of easy molecular diagnostic solutions, is pleased to announce the test menu expansion support to Departments of Health with the addition of its Candida auris assay.
-
Microbix & BioGX Collaborate on real-time PCR Assays & Controls
12/7/2023
Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces a collaboration with BioGX, Inc., a global provider of easy molecular diagnostic solutions.
-
BioGX Candida Auris PCR Assay Global Adoption Accelerates
7/24/2023
BioGX, a global provider of easy molecular diagnostic solutions, announced accelerated adoption of their high performance Sample-Ready™ PCR assay* for detection of Candida auris, a rapidly spreading, hard to treat fungus with a growing presence in hospitals and long-term care facilities.
-
BioGX Candida Auris PCR Assay Adoption Accelerates
3/23/2023
BioGX announced accelerated adoption of their high performance Sample-Ready™ PCR assay* for detection of Candida auris, a rapidly spreading, hard to treat fungus with a growing presence in hospitals and long-term care facilities.
-
BioGX Ships First Batch of pixl(TM) Real-Time PCR Platform to US Laboratories
2/28/2023
BioGX has announced fulfillment of multiple initial orders for its portable pixl™ real-time PCR platform to customers across the U.S., with immediate plans to scale production to meet market demand.
-
BioGX Launches 'pixl™' Portable qPCR Platform Ex-US With Expanded Test Menu for Infectious Diseases
12/8/2022
BioGX, a global provider of easy molecular diagnostic solutions since 2007, announced the Ex-US commercial release of its portable pixl™ qPCR real-time PCR platform for use with BioGX CE-IVD marked assays, enabling global access and complementing the recent US FDA EUA expanded use of Xfree™ COVID-19 Direct RT-PCR on the pixl.
-
BioGX Expands FDA EUA with pixl™ Portable qPCR System for its Direct-Sample COVID-19 Assay
11/10/2022
BioGX announced that the US FDA has updated their original Direct Sample Xfree™ COVID-19 Emergency Use Authorization to increase the shelf-life of the assay reagent to 15 months and expand its use to additional real-time PCR platforms, including BioGX’s pixl™ real-time PCR platform.
-
BioGX Launches CE-IVD Marked Multi-gene COVID-19 Point-of-Care Test at AACC
7/27/2022
BioGX, a global provider of easy molecular diagnostic solutions, announced the launch of a point-of-care (POC) CE-Marked, three gene multiplex COVID-19 test on its pixl platform.
-
Cepheid and BioGX Announce Collaboration to Develop Monkeypox PCR Test for the GeneXpert® System
6/27/2022
Cepheid and BioGX today announced a collaboration between the two companies to deliver a PCR test for Monkeypox that will run on the GeneXpert system.
-
BioGX COVID-19 Tests Detect Omicron SARS-CoV-2 Variant
12/6/2021
BioGX, a global provider of molecular diagnostic solutions, announced that the Omicron (B.1.1.529), the latest emerging SARS-CoV-2 variant of concern, will be detected by the portfolio of BioGX SARS-CoV-2 products that target the nucleocapsid (N-gene) and envelope (E-gene) for detection of the virus.
-
BD, BioGX Announce FDA Emergency Use Authorization Submissions for New COVID-19 Diagnostics for Use in U.S.
3/17/2020
New Diagnostics Have Potential to Increase Capacity of COVID-19 Testing in U.S. by Thousands of Tests Per Day.
-
BioGX and Launch Diagnostics Announce Distribution Partnership for U.K. and Ireland
2/8/2018
BioGX continues to expand its global presence with the announcement of a distribution partnership between BioGX's Amsterdam-based European subsidiary, BioGX B.V., and U.K.-based distributor, Launch Diagnostics.
-
BioGX BV and AxonLab AG Announce Distribution Partnership
2/6/2018
The multi-year partnership, which began Jan. 1, 2018, represents a significant step in the United States-based company's overseas growth, as many of BioGX's products will now be available to a considerably broader customer base.
-
BioGX Launches Four CE-Marked IVD Assays At The European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID)
4/24/2017
-
BioGX Launches European Subsidiary To Expand Operations Into Europe
4/24/2017
-
BioGX Receives CE-IVD Mark For Influenza A, B And Respiratory Syncytial Virus Assay On The BD MAX System
10/6/2016